Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 12/2012

01.12.2012 | Editorial Commentary

Pretreatment PET in breast cancer: is there a role?

verfasst von: Sue Chua, Ashley M. Groves

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Excerpt

Breast carcinoma shows greater heterogeneity than the vast majority of adenocarcinomas and carries a highly variable prognosis dependent on a wide range of factors, including tumour size and stage, histological subtype, grade, hormone receptor status and a growing range of molecular abnormalities. Accurate preoperative prognostication is highly important in selecting the most appropriate individualized therapy for a particular patient, and considerable interest is now being focused on noninvasive imaging as a means to achieve this. The ability of 18F-FDG PET/CT to combine functional and anatomical data has contributed enormously to oncology [1], and in particular to the emerging field of personalized medicine [2], but it has not yet found a routine role in the preoperative assessment of breast cancer. We ask here whether this situation is likely to change. …
Literatur
1.
Zurück zum Zitat Syed R, Bomanji J, Nagabushan N, Hughes S, Kayani I, Groves AM, et al. Impact of combined FDG PET on the management of head and neck tumour. Br J Cancer. 2005;92:1046–50.PubMedCrossRef Syed R, Bomanji J, Nagabushan N, Hughes S, Kayani I, Groves AM, et al. Impact of combined FDG PET on the management of head and neck tumour. Br J Cancer. 2005;92:1046–50.PubMedCrossRef
2.
Zurück zum Zitat Goh V, Engeldow A, Rodriguez-Justo M, Shastry M, Blackman G, Endozo R, et al. Assessment of primary colorectal cancer by integrated 18F-FDG PET/perfusion CT: decoupling of flow and metabolism occurs in early not late stage cancer. J Nucl Med. 2012;53:687–92.PubMedCrossRef Goh V, Engeldow A, Rodriguez-Justo M, Shastry M, Blackman G, Endozo R, et al. Assessment of primary colorectal cancer by integrated 18F-FDG PET/perfusion CT: decoupling of flow and metabolism occurs in early not late stage cancer. J Nucl Med. 2012;53:687–92.PubMedCrossRef
3.
Zurück zum Zitat Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef
4.
Zurück zum Zitat Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29.PubMedCrossRef Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29.PubMedCrossRef
5.
Zurück zum Zitat Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.PubMedCrossRef Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.PubMedCrossRef
6.
Zurück zum Zitat Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol. 2012;23:2277–82.PubMedCrossRef Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol. 2012;23:2277–82.PubMedCrossRef
7.
Zurück zum Zitat Groves AM, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T, et al. Defining the role of PET-CT in staging early breast cancer. Oncologist. 2012;17:613–9 Groves AM, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T, et al. Defining the role of PET-CT in staging early breast cancer. Oncologist. 2012;17:613–9
8.
Zurück zum Zitat Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–1627. Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–1627.
9.
Zurück zum Zitat Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii–iv. xi–267.PubMed Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii–iv. xi–267.PubMed
10.
Zurück zum Zitat Blue Cross and Blue Shield Association. FDG positron emission tomography for evaluating breast cancer. TEC Bull (Online). 2003;20:1–7. Blue Cross and Blue Shield Association. FDG positron emission tomography for evaluating breast cancer. TEC Bull (Online). 2003;20:1–7.
11.
Zurück zum Zitat Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.PubMedCrossRef Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.PubMedCrossRef
12.
Zurück zum Zitat Aukema TS, Straver ME, Valdés Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896–7. Author reply 1898–99.PubMedCrossRef Aukema TS, Straver ME, Valdés Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896–7. Author reply 1898–99.PubMedCrossRef
13.
Zurück zum Zitat Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.PubMed Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.PubMed
14.
Zurück zum Zitat De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, et al. Is [(18)F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast. 2012. doi:10.1016/j.breast.2012.05.009. De Cicco C, Gilardi L, Botteri E, Fracassi SL, Di Dia GA, Botta F, et al. Is [(18)F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? Breast. 2012. doi:10.​1016/​j.​breast.​2012.​05.​009.
15.
Zurück zum Zitat Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000.PubMedCrossRef Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000.PubMedCrossRef
16.
Zurück zum Zitat Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, et al. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem. 2011;18:5022–32.PubMedCrossRef Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, et al. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem. 2011;18:5022–32.PubMedCrossRef
17.
Zurück zum Zitat Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335–43.PubMedCrossRef Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335–43.PubMedCrossRef
18.
Zurück zum Zitat Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296–307.PubMedCrossRef Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296–307.PubMedCrossRef
19.
Zurück zum Zitat Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46–52.PubMedCrossRef Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46–52.PubMedCrossRef
20.
Zurück zum Zitat Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–9.PubMed Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–9.PubMed
21.
Zurück zum Zitat Semple SIK, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038–45.PubMedCrossRef Semple SIK, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038–45.PubMedCrossRef
22.
Zurück zum Zitat Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:416–21.PubMedCrossRef Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:416–21.PubMedCrossRef
23.
Zurück zum Zitat Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2011;2011:111–5.PubMedCrossRef Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2011;2011:111–5.PubMedCrossRef
24.
Zurück zum Zitat Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.PubMedCrossRef Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.PubMedCrossRef
Metadaten
Titel
Pretreatment PET in breast cancer: is there a role?
verfasst von
Sue Chua
Ashley M. Groves
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2216-7

Weitere Artikel der Ausgabe 12/2012

European Journal of Nuclear Medicine and Molecular Imaging 12/2012 Zur Ausgabe